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BACKGROUND: Several countries have implemented safety strategies to reduce the risk of Zika virus (ZIKV) transmission through blood transfusion. These strategies have included nucleic acid amplification testing (NAT) of blood donations. In this study, a new real-time polymerase chain reaction (PCR) assay including internal control for the detection of ZIKV on the cobas omni Utility Channel (UC) on the cobas 6800 system is presented.
STUDY DESIGN AND METHODS: PCR conditions
and primer/probe concentrations were optimized on the LightCycler 480 instrument. Optimized conditions were transferred to the cobas omni UC on the cobas 6800 system. Subsequently, the limit of detection (LOD) in plasma and urine, genotype inclusivity, specificity, crossreactivity, and clinical sensitivity were determined.
RESULTS:
The 95% LOD of the ZIKV PCR assay on the cobas 6800 system was 23.0 IU/mL (95% confidence interval [CI], 16.5-37.5) in plasma and 24.5 IU/mL (95% CI, 13.4-92.9) in urine. The assay detected African and Asian lineages of ZIKV. The specificity was 100%. The clinical concordance between the newly developed ZIKV PCR assay and the investigational Roche cobas Zika NAT test was 83% (24/29) .
CONCLUSIONS:
We developed a sensitive ZIKV PCR assay on the cobas omni UC on the cobas 6800 system. The assay can be used for large-scale screening of blood donations for ZIKV or for testing of blood donors returning from areas with ZIKV to avoid temporal deferral. This study also demonstrates that the cobas omni UC on the cobas 6800 system can be used for inhouse-developed PCR assays.
Z ika virus (ZIKV) is a flavivirus isolated in 1947
from a rhesus monkey in the Zika forest in Uganda and was identified in humans in 1952. 1, 2 Approximately 80% of the ZIKV infections remain asymptomatic or subclinical. 3 The symptoms are usually nonspecific and include fever, rash, musculoskeletal pain, headache, and conjunctivitis. 4 ZIKV infection of the central nervous system can present as meningoencephalitis. A major concern is the association of ZIKV infection with Guillain-Barr e syndrome in adults and microcephaly and other neurologic manifestations in fetuses of infected mothers. 5, 6 ZIKV is primarily transmitted to humans by the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). 7, 8 Other transmission routes are possible, including sexual, mother-to-child, and transfusionderived transmission. [9] [10] [11] The potential of ZIKV transmis- 14 Several countries with local mosquito-borne ZIKV transmission have implemented safety strategies to reduce the risk of ZIKV transmission through blood components. These strategies include donor education, temporal deferral of blood donors traveling to endemic areas, collecting blood in nonendemic areas, pathogen reduction, and nucleic acid amplification testing (NAT) of blood donations. A combination of travel deferral, pathogen reduction, and NAT has been utilized in the United States. [15] [16] [17] Recently, universal NAT screening of US blood donors for ZIKV was mandated by the Food and Drug Administration (FDA), starting with states most at risk of local transmission.
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The blood supply of countries without ZIKV-infected mosquitoes may also be at risk for ZIKV. Blood donors traveling to endemic countries may import ZIKV into the blood supply. Some countries have implemented a deferral period for donors who traveled outside the country to minimize the risk of transfusion-transmitted ZIKV infections. 16, 19 Although travel deferrals are probably an effective measure, it may cause a shortage of blood especially after the holiday season. The testing of donors returning from a ZIKVaffected area with a ZIKV polymerase chain reaction (PCR) could be used to circumvent the deferral period.
In the Netherlands, the cobas 6800 system (Roche) has been recently introduced for routine screening of blood donations for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) using the cobas MPX test. The cobas 6800 system includes the cobas omni Utility Channel (UC) that provides open channel functionality to run in-house-developed PCR assays. The designed oligonucleotides are added to a reagent cassette containing ready-to-use cobas omni reagents. Internal control (IC) oligonucleotides are included in the master mix to monitor the efficiency of nucleic acid extraction and PCR amplification. The PCR profile and other test variables can be programmed on the cobas 6800 system using dedicated software.
The intention of this study was to develop a sensitive ZIKV PCR assay on the UC of the cobas 6800 system. ZIKV-specific primers and probes were designed and PCR conditions and primer/probe concentrations were optimized with the cobas omni optimization kit (Roche) on the LightCycler 480 instrument. The selected conditions were transferred to the cobas 6800 system. Subsequently, the performance of ZIKV PCR assay on the UC of the cobas 6800 system was evaluated.
MATERIALS AND METHODS

Primer and probe design
The ZIKV PCR assay targets conserved sequences in the 3 0 -UTR region of the ZIKV genome. Table 1 . On December 20, 2016, the PCR primers and probes potential mismatches were evaluated by mapping them to ZIKV full-length sequences available in Genbank. Twenty-nine were of the African and 176 were of the Asian ZIKV lineage. The primer set in combination with the probe covering the Asian lineage showed up to five potential mismatches in 176 Asian isolates. The primer set in combination with the probe covering the African lineage showed up to maximal four potential mismatches in 29 African isolates. No mismatches were found near the 3 0 -end of the primers, which is crucial for detection through PCR.
Optimization of PCR conditions
The optimum primer/probe concentrations and the PCR cycling condition were determined on a light cycler instrument (LightCycler 480-II, Roche). Viral RNA was extracted using an extractor (NucliSens EasyMag, bioM erieux) with the NucliSens magnetic extraction reagents according to the off-board protocol, which is based on the method developed by Boom and colleagues. 20 Briefly, 850 mL of plasma was mixed with 9 mL of lysis buffer containing 6 mol/L guanidine isothiocyanate. To monitor extraction and PCR amplification efficiency, 10 mL of noncompetitive IC molecules (MS2 bacteriophage, DSMZ) was added which results in IC signals with cycle threshold (Ct) values between 35 and 40 cycles. 21 The lysis buffer tubes were incubated at 378C for 30 minutes. After 50 mL of magnetic silica particles was added, tubes were incubated at room temperature for 10 minutes. The silica particles were pelleted by centrifugation at 2228 3 g for 5 minutes. Next, the pellet was resuspended in 1.8 mL of lysis buffer and transferred to EasyMag vessels. Nucleic acid was eluted in 50 mL of elution buffer. PCR was performed on the LightCycler 480-II using an optimization kit (cobas omni, Roche). The cobas omni optimization kit contains the same reagents as present in the reagent cassette of the cobas omni UC on the cobas 6800 system. The total volume of one PCR procedure was 52 mL and consisted of 15 mL of master mix reagent 2 (MMx-R2), 10 mL of manganese acetate (MMx-R1), and 27 mL of nucleic acid. The optimal primers and probe concentrations were 500 nmol/L for each primer and 80 nmol/L for each probe (data not shown). The reverse transcription (RT)-PCR protocol consisted of reverse transcription for 7 minutes at 558C and 7 minutes at 658C, followed by 50 cycles of 5 seconds at 918C and 40 seconds at 608C.
ZIKV PCR test on the cobas omni UC on the cobas 6800 system
The UC on the cobas 6800 system is an open channel that utilizes a preassembled reagent cassette consisting of five containers including one empty container. The reagent cassette was prepared according to the manufacturer's instructions. Four containers contain protease solution, IC solution containing armored RNA molecules in MS2 bacteriophage, elution buffer, and MMx-R1 (manganese acetate), respectively. MMx-R2 was added in the empty container. MMx-R2 was prepared as follows: 8 mL of the cobas omni UC MMx-R2, which includes primers and probe for amplification and detection of the IC, was mixed gently for 5 minutes. Subsequently, 140 lL of each primer (100 lmol/L), 22 lL of each probe (100 lmol/L), and 156 lL H 2 O was added and mixed for an additional 5 minutes. Finally, 7 mL of the prepared master mix was transferred to the empty container of a cobas omni UC reagent kit cassette. The cobas omni UC tool software (version 1.0, Roche) was used to put the PCR profile, sample type/input volume, and relative fluorescence increase (RFI value) cutoff value on the cobas 6800 system. Results interpretation is defined by the algorithm of the UC tool software based on the RFI value. The sample input volume and the RFI were set on 850 mL and 1.07, respectively. The cobas omni UC tool software was also used to label the assay name on the cassette radiofrequency identification tag which enables the cassette to be identified by the cobas 6800 system.
Analytical sensitivity
The analytical sensitivity was determined by testing 0.5 log dilution series of the World Health Organization (WHO) international standard (IS) for ZIKV RNA (WHO ZIKV IS) for NAT assays (11468/16, Paul-Ehrlich-Institute). 22 The dilutions were prepared in negative pooled plasma and in urine (from one individual). The WHO ZIKV IS is a heat-inactivated and lyophilized cell culturederived preparation from the French Polynesian ZIKV strain (Asian lineage). The assigned unitage is 5 3 10 7 IU/ mL. The WHO ZIKV IS was diluted in negative human plasma in half-log increments to concentrations spanning the previously determined endpoint. The dilutions consisted of five concentrations ranging from 50 to 0.5 IU/mL and were tested in two independent sets of 24 replicates per dilution (total 48 replicates). For urine one set of 12 replicates per dilution was tested. The plasma or urine input volume was 850 lL. The 95% limit of detection (LOD) was determined by Probit regression analysis using computer software (SPSS Statistics, Version 23, IBM Corp.) with 10-log converted input concentrations.
Clinical sensitivity
The 29 clinical plasma samples used in this study were from the Medical Laboratory Services (Willemstad, Curaao). The plasma samples were derived from individuals suspected of ZIKV infection by the general practitioner. The samples were shipped to Sanquin and kept at less than -208C until processing. At Sanquin, the samples were tested with the ZIKV PCR and with the investigational cobas Zika test (Roche). 23 The cobas Zika test was developed for the detection of ZIKV RNA in blood donor plasma samples using the cobas 6800/8800 systems and was recently licensed by the FDA for routine ZIKV donor screening in the United States. 24, 25 Due to limited sample volume, 0.2 mL of plasma of each sample was first diluted in 1.8 mL of negative human plasma. The 103 diluted samples were tested with both ZIKA assays on the cobas 6800 system. The input volume was 850 mL per sample for both assays. The samples were identified using the cobas Zika test. The samples were tested neat and in 10-fold dilutions.
Specificity of the ZIKV PCR on the cobas 6800
The specificity of the primer/probe set for the ZIKV PCR assay was evaluated by testing of 186 ZIKV-negative individual Dutch blood donor samples (healthy blood donors from a nonendemic area). In addition, the potential crossreactivity with other blood transmittable and arboviruses was evaluated by testing sets of the following plasma samples and concentration ranges: 53 HCV samples (4 3 10 To ensure the ubiquity of the designed primer/probe set to detect African and Asian ZIKV strains, different ZIKV isolates from both lineages were tested. The testing included two African ZIKV strains isolated from Uganda, MR 766 and MP 1751. 1, 26 The ZikaSPH2015 strain from
Brazil and PF13/251013-18 (the WHO ZIKV IS) isolated from French Polynesia represented the Asian ZIKV lineage. 27, 28 The viral load of the four tested ZIKV isolates was approximately 100 copies/mL. This was based on the Ct difference between the sample and the IS as explained earlier.
In addition, a 12-member panel containing ZIKV, CHIKV, yellow fever virus, and DENV (Type 1) was tested with the ZIKV PCR. This panel was used for the external quality assessment for the ZikAlliance Project (Emergence des Pathologies Virales, University of Marseille). The panel consists of freeze-dried material that was reconstituted in 200 mL of water according to the manufacturers' instructions. To 100 mL of the reconstituted material, 900 mL of negative human plasma was added. One milliliter was tested in the cobas ZIKV PCR on the cobas 6800. This was done in duplicate.
RESULTS
Analytical sensitivity
The LOD of the ZIKV PCR assay was determined by analyzing serial dilutions in plasma or urine of the candidate WHO ZIKV IS on the cobas omni UC of the cobas 6800 system. The number and percentage of positive results of each concentration for 48 replicates are shown in Table 2 . The data in this table were used for Probit analyses. For plasma, the ZIKV PCR assay demonstrated a 95% LOD of 23.0 IU/mL (95% confidence interval [CI], 16.5-37.5). The 50% hit rate was 5.3 IU/mL (95% CI, 4.3-6.6). For urine, the ZIKV PCR assay demonstrated a 95% LOD of 24.5 IU/mL (95% CI, 13.4-92.9). The 50% LOD was 5.4 IU/mL (95% CI, 3.3-8.8).
Clinical sensitivity
The 29 clinical samples obtained from suspected naturally infected individuals were analyzed simultaneously with the ZIKV PCR and the Roche cobas Zika test for use on the cobas 6800/8800 systems. The results are shown in Table  3 . A total of 13 of 29 (45%) were reactive with the ZIKV PCR assay and the cobas Zika test. Furthermore, 11 of 29 samples (38%) were nonreactive in both PCR assays.
Five samples (17%) showed discrepant results: two samples were only reactive with the ZIKV PCR assay and three samples were only reactive with the cobas Zika test. The discrepant samples showed high Ct values (>37.4) indicating very low ZIKV RNA loads. At low ZIKV RNA levels discrepancies can be expected. Due to insufficient sample volume, it was not possible to retest the discrepant samples. Table 4 shows the results of the 10 blood donor samples from Puerto Rico. The Ct values of the cobas Zika test and the ZIKV PCR on neat samples were quite similar.
Specificity
The ZIKV PCR assay showed a specificity of 100% when testing 186 ZIKV-negative blood donor samples. All 186 samples were nonreactive in the ZIKV PCR assay and showed a valid IC signal. The average Ct value of the IC curves was 31.14 cycles (SD, 0.4 cycles). Potential cross-reactivity of the ZIKV PCR assay was evaluated by testing samples containing other viruses. The ZIKV PCR assay on the cobas omni UC on the cobas 6800 system showed no cross-reactivity with CHIKV, DENV, HBV, HCV, HEV, HAV, HIV, parvovirus B19, and WNV. All samples showed a valid IC signal.
All four ZIKV isolates tested in this study were reactive in the ZIKV PCR assay. The Ct value of the samples, with an approximate viral load of 100 copies/mL, ranged from 34.2 to 36.6. These findings indicate that the assay is able to detect strains from both the African and Asian ZIKV lineage. Table 5 shows the results of the ZIKV PCR on the 12-member external quality assessment panel. The results also illustrate that the ZIKV PCR is able to detect both ZIKV lineages. Furthermore they show that the ZIKV PCR is specific for ZIKV.
DISCUSSION
This study evaluates the performance of a new PCR assay for the detection of ZIKV RNA using the open channel functionality of the cobas omni UC on the cobas 6800 system. The cobas 6800 system is a fully automated highthroughput NAT system including all required processing steps. The system also offers the opportunity to run inhouse-developed PCR assays on the cobas omni UC. The cobas 6800 system was recently introduced in the Netherlands for routine blood donor screening for HBV, HCV, and HIV. The cobas 6800 system uses a generic nucleic acid extraction method. To our knowledge this is the first report of an in-house assay applied on the cobas omni UC on the cobas 6800 system.
The ZIKV PCR assay LOD was not significantly different in plasma and urine as determined on testing serial dilutions of the ZIKV IS. The ZIKV PCR assay LOD was 23.0 IU/mL (95% CI, 16.5-37.5) in plasma and 24.5 IU/mL (95% CI, 13.4-92.9) in urine. This is the first study using the WHO ZIKV IS. Therefore, it is difficult to compare our assay with previously published ZIKV PCR assays. However, a recent study compared nine published ZIKV PCR assays using a synthetic universal control RNA construct containing the target regions of each assay. 29 Extrapolation of the findings of this study to viral loads and accommodating the loads to our input and extraction volume, the LOD of eight assays out of nine ranged between 20 and 170 copies/mL. The ninth assay had an extrapolated LOD of 13,800 copies/mL. Assuming that one copy is equivalent to 1 IU, our ZIKV PCR assay shows comparable sensitivity with most ZIKV PCR assays included in this comparative study. The availability of the WHO ZIKV IS will allow a much better comparison of the sensitivity of the available ZIKV NAT assays. The ZIKV PCR assay was highly specific and showed no cross-reactivity with several other viruses. Moreover, all subjected ZIKV strains in this study were reactive, indicating that the assay would detect sequence variants of African and Asian ZIKV lineages. 1, [26] [27] [28] The applied primers target a highly conserved part of the 3 0 -UTR region and only show a few potential mismatches with currently available ZIKV sequences. The potential mismatches were not located at the 3 0 -end of the primer, which is crucial for amplification. In addition, to anticipate future ZIKV variants, the assay is designed with two probes, which will permit ZIKV detection in case of new nucleotide mismatches. When the assay was performed with only one of the probes the assay still had approximately the same sensitivity and could detect strains from both lineages (data not shown). However, as the assay has been evaluated with a limited number of isolates, further validation with additional field isolates is needed. The evaluation of the 29 clinical samples shows that the ZIKV PCR assay was in 83% of the cases concordant with the investigational Roche cobas Zika test. The reason for the five discrepancies remains uncertain. The relatively high Ct values of the discrepant reactive results are indicative of a low sample ZIKV RNA load, which could be an explanation for the observed discrepancies. The information concerning the time between onset of symptoms and sample collection was not available. Therefore, the 11 negative results could be a result of patients not having a ZIKV infection or due to ZIKV RNA clearance by the patient. The nonreactive result could also be explained by the low viral load as a consequence of 103 predilution of the samples before testing. As mentioned, due to the limited sample amount it was not possible to retest the samples.
Sanquin applies a 28-day deferral period for donors returning from travel outside of Europe to prevent donation by donors with asymptomatic viremia of known and unknown infectious diseases. Donors traveling within Europe are not deferred unless they have traveled to an area determined by the Dutch blood transfusion service as risk area for infectious diseases. This precaution measure was recently implemented during the WNV outbreak, which affected parts of Europe. Although this deferral policy is cost-effective and safe and can be implemented rapidly, it can have a significant impact on donor availability, especially after the holiday seasons. 19, 30 Therefore, in the future it might be necessary to selectively test donors with a recent travel history with a NAT for the endemic viruses and release the blood when the result is nonreactive. This may also apply for countries endemic for ZIKV. After the WNV outbreak, some European countries have introduced a selectively WNV NAT based on travel history. 31 The risk of a ZIKV outbreak in Europe is feasible since one of its vectors, Ae. albopictus, is present in South Europe and ZIKV imported cases into Europe have been reported. 32 In case of a ZIKV outbreak in Europe, the ZIKV PCR can be used for selective ZIKV testing of traveling donors to avoid deferral. Selective testing of donors returning from affected regions is an alternative, in case deferral leads to an unacceptable decrease of donor availability.
In the near future we plan to extend our ZIKV PCR to a multiplex RT-PCR assay for the simultaneous detection of ZIKV, DENV, and CHIKV on the cobas omni UC on the cobas 6800 system. These three arboviruses manifest similar clinical symptoms, share common vectors, and are reported to cocirculate in regions of the Americas. 33 WHO recently published a target profile for ZIKV PCR assays and one of the desired characteristics for an optimal ZIKV diagnostic test is a multiplex PCR of these three arboviruses. 34 Ideally, the arbo-PCR multiplex also includes WNV. Recently, three multiplex assays targeting ZIKV, DENV, and CHIKV have been published, including one released by the Centers for Disease Control and Prevention under an emergency authorization. [35] [36] [37] None of the three multiplex PCRs was evaluated with the cobas omni UC reagents on the cobas 6800 system. Partially or complete adoption and/or modification of the primer sets used by one of three published multiplex PCRs could be an alternative for a new primer design covering DENV and CHIKV.
In conclusion, the ZIKV PCR assay on the cobas omni UC of the cobas 6800 system provides sensitive detection of ZIKV RNA in plasma and urine and covers both the African and the Asian lineages. The cobas 6800 system is suitable for high-and low-throughput blood donor screening for ZIKV RNA in endemic and nonendemic countries. The assay is easy to implement on the cobas 6800 and probably cheaper compared to currently available commercial ZIKV assays. Furthermore it gives blood banks flexibility in rapidly developing high-throughput inhouse NAT assays for emerging infectious diseases for which no commercial tests are (yet) available.
